Quote | Janux Therapeutics Inc. (NASDAQ:JANX)
Last: | $47.10 |
---|---|
Change Percent: | -0.53% |
Open: | $47.76 |
Close: | $47.10 |
High: | $47.97 |
Low: | $46.79 |
Volume: | 669,086 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
News | Janux Therapeutics Inc. (NASDAQ:JANX)
2024-05-13 10:30:04 ET Wedbush analyst issues BUY recommendation for JANX on May 13, 2024 09:00AM ET. The previous analyst recommendation was Buy. JANX was trading at $49.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst ...
2024-05-07 17:59:35 ET More on Janux Therapeutics Janux Therapeutics: A Prime Target In Cancer Care's M&A Game Janux Therapeutics: Yes There's New Data; No It's Not A Buy Here Trial Data Triggers Massive Rally In Janux Therapeutics Janux Therapeutics gain...
Message Board Posts | Janux Therapeutics Inc. (NASDAQ:JANX)
Subject | By | Source | When |
---|---|---|---|
Didn't you mean to say that "things are | mmayr | investorshub | 04/23/2008 12:00:44 AM |
That's a bunch of BS. I wish | mmayr | investorshub | 04/22/2008 11:55:49 PM |
To All Janex Shareholders: | isisevan | investorshub | 09/23/2005 7:28:13 PM |
Looks to me like this "Vince" character has | mmayr | investorshub | 08/21/2002 11:58:14 AM |
Hello pontang | Wise Investment | investorshub | 08/01/2002 6:57:26 PM |
News, Short Squeeze, Breakout and More Instantly...
Janux Therapeutics Inc. Company Name:
JANX Stock Symbol:
NASDAQ Market:
2024-05-13 10:30:04 ET Wedbush analyst issues BUY recommendation for JANX on May 13, 2024 09:00AM ET. The previous analyst recommendation was Buy. JANX was trading at $49.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst ...
Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer Enrollment ongoing for EGFR-TRACTr (JANX008) in solid tumors Update on JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024 $651.8 million in cash and cash equivalents and short-term...
2024-04-30 00:06:00 ET Janux Therapeutics (NASDAQ: JANX) stock price has gone vertical this year, making it one of the top-performing biotech companies in Wall Street. It jumped to a high of $61 on Monday about 975% above the lowest point in 2023, giving it a market cap of over $2.4...